Clinical Candidates

Domvanalimab (dom) is an Fc-silent investigational monoclonal antibody. AB308 is an Fc-enabled investigational anti-TIGIT monoclonal antibody. Both bind to TIGIT and may enable CD155:CD226 interaction and subsequent immune cell activation.

Etrumadenant (etruma) is an investigational small molecule, dual A2A/A2B adenosine receptor antagonist. Quemliclustat (quemli) is an investigational small molecule CD73 inhibitor. AB598 is an investigational anti-CD39 antibody. Adenosine is an immunosuppressive substance produced inside tumors as a result of rapid cancer cell turnover and, in some cases, in connection with certain antitumor interventions, such as chemotherapy and radiation.

Zimberelimab (zim) is an investigational monoclonal antibody that binds PD-1 and may restore the antitumor activity of T cells.

AB521 is an investigational small-molecule inhibitor of the hypoxic transcriptional regulator HIF-2a that has demonstrated potent antitumor activity in xenograft models of cancer.